When to Move Beyond TACE: The Expanding Role of Systemic Therapy in Intermediate-Stage HCC
Panelists discuss how combining systemic therapy with locoregional treatments like transarterial chemoembolization (TACE) aims to enhance therapeutic efficacy by addressing its limitations, such as incomplete tumor necrosis and hypoxia-induced progression. Tyrosine kinase inhibitors (TKIs) like lenvatinib and immune checkpoint inhibitors (ICIs) counteract TACE-induced resistance by inhibiting angiogenesis and boosting immune response, improving overall tumor control.
Video content above is prompted by the following:
- In recent years, several trials have sought to evaluate the potential synergy of combining systemic therapy with locoregional therapy. Please discuss the rationale for combining systemic therapy with locoregional treatments like TACE.
- What are the limitations of TACE monotherapy?
- How do TKIs like lenvatinib or ICIs contribute to overcoming TACE-induced tumor progression/resistance mechanisms?
- How does this combination potentially enhance treatment efficacy compared with TACE alone?
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
